Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Oncogene

• Publication date

  2003-11-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1206919PMID 14647474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The JNK signal transduction pathway.

  2007cited by this paper
• JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells*

  2003cited by this paper
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  2003cited by this paper
• Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.

  2003cited by this paper
• NF-κB as a Therapeutic Target in Multiple Myeloma*

  2002cited by this paper
• Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

  2002cited by this paper
• Molecular mechanisms of novel therapeutic approaches for multiple myeloma

  2002cited by this paper
• Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• Integrating stress-response and cell-cycle checkpoint pathways.

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

  2001cited by this paper
• SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

  2001cited by this paper
• c-Jun NH2-terminal Kinase Activation Leads to a FADD-dependent but Fas Ligand-independent Cell Death in Jurkat T Cells*

  2001cited by this paper
• c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.

  2001cited by this paper
• Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

  2001cited by this paper
• Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-xL in Response to DNA Damage*

  2000cited by this paper
• The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.

  2000cited by this paper
• Inhibition of c-Jun N-Terminal Kinase 2 Expression Suppresses Growth and Induces Apoptosis of Human Tumor Cells in a p53-Dependent Manner

  2000cited by this paper
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

  2000cited by this paper
• Control of cell cycle progression by c-Jun is p53 dependent.

  1999cited by this paper
• JNK/SAPK activity contributes to TRAIL-induced apoptosis

  1999cited by this paper
• Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.

  1997cited by this paper
• IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

  1997cited by this paper
• Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

  1996cited by this paper
• Interleukin-6 inhibits apoptosis of malignant plasma cells.

  1995cited by this paper
• Interleukin-6 in human multiple myeloma.

  1995influential reference
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993cited by this paper
• Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226.

  1993cited by this paper
• TRENDS

  1948cited by this paper

• Review Article: Efficacy and Safety of JNK Inhibitors in Cancer Therapy.

  2025cites this paper
• The Role of the Dysregulated JNK Signaling Pathway in the Pathogenesis of Human Diseases and Its Potential Therapeutic Strategies: A Comprehensive Review

  2024cites this paper
• An overview of pim kinase as a target in multiple myeloma

  2023cites this paper
• Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma?

  2022cites this paper
• Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic Leukemia Cell Lines

  2022cites this paper
• Effects of Holliday Junction-Recognition Protein-Mediated C-Jun N-Terminal Kinase/ Signal Transducer and Activator of Transcription 3 Signaling Pathway on Cell Proliferation, Cell Cycle and Cell Apoptosis in Bladder Urothelial Carcinoma.

  2022cites this paper
• Pathophysiological Significance of WDR62 and JNK Signaling in Human Diseases

  2021cites this paper
• Overcoming drug resistance by targeting protein homeostasis in multiple myeloma

  2021cites this paper
• JNK signaling as a target for anticancer therapy

  2021cites this paper
• NOD2/c-Jun NH2-Terminal Kinase Triggers Mycoplasma ovipneumoniae-Induced Macrophage Autophagy

  2020cites this paper
• Acute immune stress improves cell resistance to chemical poison damage in SP600125-induced polyploidy of fish cells in vitro.

  2019cites this paper
• Emulsified isoflurane induces release of cytochrome C in human neuroblastoma SHSY-5Y cells via JNK (c-Jun N-terminal kinases) signaling pathway.

  2018cites this paper
• Thromboxane A2 Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing p38/c-Jun N-terminal Kinase (JNK) Mitogen-activated Protein Kinase (MAPK)-mediated G2/M Progression Delay and Cell Apoptosis*

  2016cites this paper
• Effect of JNK inhibitor SP600125 on hair cell regeneration in zebrafish (Danio rerio) larvae

  2016cites this paper
• JNK Inhibition Inhibits Lateral Line Neuromast Hair Cell Development

  2016cites this paper
• Effect of SP600125 on the mitotic spindle in HeLa Cells, leading to mitotic arrest, endoreduplication and apoptosis

  2016cites this paper
• Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

  2015cites this paper
• Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells

  2015cites this paper
• Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing p 38 / JNK MAP Kinase Mediated-G 2 / M Progression Delay and Cell Apoptosis

  2015cites this paper
• JNK signalling in cancer: in need of new, smarter therapeutic targets

  2014cites this paper
• Krüppel‐like factor 6 interferes with cellular transformation induced by the H‐ras oncogene

  2014cites this paper
• Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells.

  2013cites this paper
• Feasibility study: Phosphospecific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma

  2013cites this paper
• Signalling Pathways of β-Catenin/JNK in Carcinogenesis

  2013cites this paper
• Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma

  2013cites this paper
• Toosendanin induces apoptosis through suppression of JNK signaling pathway in HL-60 cells.

  2013cites this paper
• Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma

  2012cites this paper
• Toll-like receptor 4 activates NF-κB and MAP kinase pathways to regulate expression of proinflammatory COX-2 in renal medullary collecting duct cells.

  2012cites this paper
• The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma

  2011cites this paper
• Novel IκB kinase inhibitors for treatment of nuclear factor-κB-related diseases

  2011cites this paper
• Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease

  2011cites this paper
• Medicinal and Computational Chemistry Dept

  2011cites this paper
• Role of p21 in SP600125-induced cell cycle arrest, endoreduplication, and apoptosis

  2011cites this paper
• Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.

  2011cites this paper
• Immunoglobulin Gene Rearrangements, Oncogenic Translocations, B-Cell Receptor Signaling, and B Lymphomagenesis

  2010cites this paper
• CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells

  2010cites this paper
• A JNK inhibitor SP600125 induces defective cytokinesis and enlargement in P19 embryonal carcinoma cells

  2009cites this paper
• JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125

  2009cites this paper
• Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells

  2009cites this paper
• Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions

  2009cites this paper
• The Links between Transcription, β-catenin/JNK Signaling, and Carcinogenesis

  2009cites this paper
• Inhibition of NFkappaB by activated c-Jun NH2 terminal kinase 1 acts as a switch for C2C12 cell death under excessive stretch

  2009cites this paper
• Oral Administration of Blueberry Inhibits Angiogenic Tumor Growth and Enhances Survival of Mice with Endothelial Cell Neoplasm

  2009cites this paper
• A yeast 2-hybrid screen to identify and characterize interaction partners of the cancer associated protein retinoblastoma binding protein 6

  2009cites this paper
• Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma

  2009cites this paper
• JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis

  2009influential citation
• Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells

  2008cites this paper
• Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals.

  2008cites this paper
• Bcl-2 overexpression attenuates SP600125-induced apoptosis in human leukemia U937 cells.

  2008cites this paper
• Chapter 4 JNK is constitutively active in mantle cell lymphoma : cell cycle deregulation and polyploidy by JNK inhibitor SP 600125

  2008cites this paper
• Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis.

  2008cites this paper
• Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway.

  2008cites this paper
• Bortezomib inhibits human osteoclastogenesis

  2007cites this paper
• The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease

  2007cites this paper
• Towards a new age in the treatment of multiple myeloma

  2007cites this paper
• The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

  2007cites this paper
• ORIGINAL ARTICLE Bortezomib inhibits human osteoclastogenesis

  2007cites this paper
• Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells

  2007cites this paper
• Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.

  2007cites this paper
• Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma

  2007cites this paper
• Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition.

  2007cites this paper
• B Inhibition κ Factor-- Terminal Kinase Activation and Nuclear 2 by c-Jun NH Regulation of PTEN Expression in Intestinal Epithelial Cells

  2007cites this paper
• Polarity proteins PAR6 and aPKC regulate cell death through GSK-3β in 3D epithelial morphogenesis

  2007cites this paper
• A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis.

  2007cites this paper
• NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.

  2007cites this paper
• JNK regulation of oncogenesis.

  2006cites this paper
• RASSF1A suppresses oncogenic H-Ras-induced c-Jun N-terminal kinase activation.

  2006cites this paper
• NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

  2006cites this paper
• New Frontiers in the Treatment of Multiple Myeloma

  2006cites this paper
• Mechanisms of Glucocorticoid Actions and Resistance in Multiple Myeloma

  2006cites this paper
• Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists.

  2006cites this paper
• Induction of apoptosis and cell cycle arrest by a specific c-Jun NH2-terminal kinase (JNK) inhibitor, SP-600125, in gastrointestinal cancers.

  2006cites this paper
• Activation of the Jun N-Terminal Kinase Pathway by Friend Spleen Focus-Forming Virus and Its Role in the Growth and Survival of Friend Virus-Induced Erythroleukemia Cells

  2005cites this paper
• Identification and validation of novel therapeutic targets for multiple myeloma.

  2005cites this paper
• RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression.

  2005cites this paper
• Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NFκB activation and cyclin D1 up-regulation

  2005cites this paper
• Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NFkappaB activation and cyclin D1 up-regulation.

  2005cites this paper
• c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells.

  2005cites this paper
• NF- (cid:1) B as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145

  2005cites this paper
• A Suppresses the c-Jun-NH 2-Kinase Pathway and Inhibits Cell Cycle Progression

  2005cites this paper
• Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines.

  2004cites this paper
• p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

  2004influential citation